Baricitinib phosphate

Selective JAK1 and JAK2 inhibitor

Baricitinib is a selective JAK1 and JAK2 inhibitor. IC_{50} values are 5.9nm for JAK1, and 5.7nM for JAK2. In cell based assays Baricitinib/INCB-28050 demonstrated inhibition of intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations of < 50 nM, and also showed good efficacy in a number of animal models at doses of 10mg/kg and below. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy.

Ordering Information


Order Online »

ENZ-CHM198-0001

1mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Short Term Storage +4°C

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name INCB028050, LY3009104, 2-[1-Ethylsulfonyl-3-[4-(7H-

pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-

yl]acetonitrile

Appearance White powder.

CAS 1187595-84-1

Couple Target JAK

Couple Type Inhibitor

Formula $C_{16}H_{17}N_7O_2S \cdot H_3PO_4$

Identity Determined by EM-MS, NMR

MW 469.4

Purity ≥99% (HPLC)

Soluble in DMSO (74mg/ml) or ethanol (1mg/ml).

Last modified: May 29, 2024

